These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 3084166

  • 1. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
    Alvarez F, Brache V, Tejada AS, Faúndes A.
    Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
    [Abstract] [Full Text] [Related]

  • 2. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A, Brache V, Tejada AS, Cochon L, Alvarez-Sanchez F.
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [Abstract] [Full Text] [Related]

  • 3. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM, Segal S, Salem HT, Ghaneimah SA, Khalifa EA, Ahmed AG.
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [Abstract] [Full Text] [Related]

  • 4. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
    Alvarez F, Brache V, Faundes A, Tejada AS, Thevenin F.
    Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
    [Abstract] [Full Text] [Related]

  • 5. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
    Brache V, Alvarez-Sanchez F, Faundes A, Tejada AS, Cochon L.
    Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
    [Abstract] [Full Text] [Related]

  • 6. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K, Lunell NO, Zador G.
    Gynecol Obstet Invest; 1978 Feb; 9(6):304-11. PubMed ID: 754992
    [Abstract] [Full Text] [Related]

  • 7. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF, Mishell DR, Stanczyk FZ, Goebelsmann U.
    Am J Obstet Gynecol; 1977 Sep 15; 129(2):133-40. PubMed ID: 900174
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O, Gordon K, Williams RF, Hodgen GD.
    Contraception; 1996 Jan 15; 53(1):55-64. PubMed ID: 8631191
    [Abstract] [Full Text] [Related]

  • 9. Correlation between the serum norethindrone (NET) levels attained after insertion of a silastic implant releasing norethindrone acetate and the endogenous hormones particularly progesterone.
    Laumas V, Jain AK, Jha P, Rahman SA, Kumar D, Malik BK, Sarkar NN, Takkar D, Hingorani V, Laumas KR.
    Contraception; 1981 Feb 15; 23(2):211-25. PubMed ID: 6786828
    [Abstract] [Full Text] [Related]

  • 10. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
    Landgren BM, Johannisson E, Aedo AR, Kumar A, Shi YE.
    Contraception; 1989 Mar 15; 39(3):275-89. PubMed ID: 2496951
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A, Faure N, Labrie F, Fazekas AT.
    Fertil Steril; 1985 Jun 15; 43(6):868-77. PubMed ID: 3158551
    [Abstract] [Full Text] [Related]

  • 12. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B, Zeng T, Wu S, Sun H, Xiao N.
    Contraception; 1995 Jun 15; 51(6):359-65. PubMed ID: 7554977
    [Abstract] [Full Text] [Related]

  • 13. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK, Kirkman RJ, Arce BB, McNeilly AS, Loudon NB, Baird DT.
    Contraception; 1986 Nov 15; 34(5):513-22. PubMed ID: 3102162
    [Abstract] [Full Text] [Related]

  • 14. LH, FSH, estradiol and progesterone levels after discontinuation of hormonal contraception.
    Balogh A, Ditrói F, Lampé LG.
    Acta Univ Palacki Olomuc Fac Med; 1981 Nov 15; 101():95-101. PubMed ID: 6242699
    [Abstract] [Full Text] [Related]

  • 15. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.
    Nilsson CG, Lähteenmäki P, Luukkainen T.
    Contraception; 1980 Mar 15; 21(3):225-33. PubMed ID: 6771090
    [Abstract] [Full Text] [Related]

  • 16. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
    Landgren BM, Diczfalusy E.
    Contraception; 1984 May 15; 29(5):437-46. PubMed ID: 6430642
    [Abstract] [Full Text] [Related]

  • 17. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
    Scott JA, Brenner PF, Kletzky OA, Mishell DR.
    Am J Obstet Gynecol; 1978 Apr 01; 130(7):817-21. PubMed ID: 345817
    [Abstract] [Full Text] [Related]

  • 18. Effects of combined oral contraceptive steroids on pituitary-ovarian function during the menstrual cycle of lactating women.
    Ryu K, Yu HK, Kwak HM, Hong SS.
    Contraception; 1983 Mar 01; 27(3):299-310. PubMed ID: 6406140
    [Abstract] [Full Text] [Related]

  • 19. Intravaginal contraception with the synthetic progestin, R2010.
    Toivonen J.
    Contraception; 1979 Nov 01; 20(5):511-8. PubMed ID: 527342
    [Abstract] [Full Text] [Related]

  • 20. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
    Croxatto HB, Diaz S, Pavez M, Miranda P, Brandeis A.
    Acta Endocrinol (Copenh); 1982 Oct 01; 101(2):307-11. PubMed ID: 6814139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.